BeStock  
Stocks › Biotechnology › STOK

Stoke Therapeutics STOK

US equityMarket cap rank #2770Biotechnology
$26.81 −$0.12 (-0.45%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.40 +2.20%
Open$26.39
Prev close$26.93
Day range$25.94 – $27.78
Volume615.8K
Market cap$1.75B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$11.26M+5.9% YoY
Operating profit-$77.32M-79.4% YoY
Net profit-$73.64M-92.0% YoY
Diluted EPS-$1.08-66.2% YoY
Free cash flow-$65.54M-114.9% YoY
Operating cash flow-$62.69M

Revenue, last 8 quarters

$22.6MDec '24$158.6MMar '25$13.8MJun '25$10.6MSep '25$1.4MDec '25$6.2MMar '26$9.3MJun '26$11.3MSep '26

Net profit, last 8 quarters

$-10.5MDec '24$112.9MMar '25$-23.5MJun '25$-38.3MSep '25$-57.9MDec '25$-50.0MMar '26$-61.6MJun '26$-73.6MSep '26

Diluted EPS by quarter

-0.18Dec '241.90Mar '25-0.40Jun '25-0.65Sep '25-1.00Dec '25-0.79Mar '26-0.93Jun '26-1.08Sep '26

Free cash flow by quarter

$-23.2MDec '24$131.7MMar '25$-25.6MJun '25$-30.5MSep '25$-30.7MDec '25$-60.9MMar '26$-58.6MJun '26$-65.5MSep '26

Annual revenue

$0.0FY20$0.0FY21$12.4MFY22$8.8MFY23$36.6MFY24$184.4MFY25

Profitability & balance sheet

Operating margin-913.2%
Net margin-862.1%
Return on equity-73.6%
Return on assets-63.4%
Return on invested capital-73.2%
Current ratio7.24
Liabilities / assets13.3%
Cash & investments$319.19M
Net cash (debt)$319.19M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $11.26M $9.33M $6.23M $184.42M $1.40M
Total Operating Revenue $11.26M $9.33M $6.23M $184.42M $1.40M
Operating Expense $88.57M $74.75M $59.65M $205.01M $62.84M
Selling and Admin Expenses $28.74M $25.25M $19.97M $67.09M $21.15M
Research & Development $59.83M $49.50M $39.67M $137.92M $41.70M
Operating Profit -$77.32M -$65.43M -$53.42M -$20.59M -$61.44M
Net Non-Operating Interest Income (Expense) $3.67M $3.50M $3.40M $13.76M $3.62M
Total Other Finance Costs -$3.67M -$3.50M -$3.40M -$13.76M -$3.62M
Other Income (Expense) $6,000.00 $308,000.00 $18,000.00 -$51,000.00 -$110,000.00
Other Non-Operating Income (Expenses) $6,000.00 $308,000.00 $18,000.00 -$51,000.00 -$110,000.00
Pretax Profit -$73.64M -$61.62M -$50.00M -$6.89M -$57.93M
Tax $0.00 $0.00 $0.00 – –
Net Profit -$73.64M -$61.62M -$50.00M -$6.89M -$57.93M
Profit from Continuing Operations -$73.64M -$61.62M -$50.00M -$6.89M -$57.93M
Net Income to Parent Company -$73.64M -$61.62M -$50.00M -$6.89M -$57.93M
Net Income to Common Stockholders -$73.64M -$61.62M -$50.00M -$6.89M -$57.93M
Basic EPS -$1.08 -$0.93 -$0.79 -$0.12 -$1.00
Diluted EPS -$1.08 -$0.93 -$0.79 -$0.12 -$1.00
-General & Admin Expense – $25.25M $19.97M $67.09M –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $406.69M $393.97M $443.28M $418.43M $418.43M
Total Current Assets $354.42M $322.54M $366.68M $305.70M $305.70M
Cash and Cash Equivalents & Short-Term Investments $319.19M $292.82M $343.55M $284.67M $284.67M
-Cash and Cash Equivalents $107.27M $110.00M $155.66M $84.22M $84.22M
-Short Term Investments $211.92M $182.81M $187.89M $200.45M $200.45M
Receivables $10.08M $8.72M $6.14M $7.91M $7.91M
-Accounts Receivable $8.54M $7.18M $4.45M $5.94M $5.94M
-Accrued Interest Receivable $1.53M $1.54M $1.69M $1.97M $1.97M
Prepaid Assets $17.60M $14.69M $10.12M $8.74M $8.74M
Other Current Assets $7.56M $5.82M $6.39M $3.90M $3.90M
Total Non-Current Assets $52.28M $71.43M $76.60M $112.73M $112.73M
Net PPE $9.45M $6.70M $5.89M $6.25M $6.25M
-Gross PPE $9.45M $6.70M $5.89M $16.39M $16.39M
Investments and Advances $39.60M $61.50M $67.48M $106.26M $106.26M
-Available for Sale Securities $39.60M $61.50M $67.48M $106.26M $106.26M
Other Non-Current Assets $3.23M $3.23M $3.23M $227,000.00 $227,000.00
Total Liabilities $54.10M $48.42M $48.40M $65.98M $65.98M
Total Current Liabilities $48.98M $41.93M $40.81M $57.88M $57.88M
Payables $4.03M $4.79M $6.84M $4.94M $4.94M
-Accounts Payable $4.03M $4.79M $6.84M $4.94M $4.94M
Current Accrued Expenses $25.42M $18.49M $16.89M $22.99M $22.99M
Short-Term Debt and Capital Lease Obligation $1.24M $1.85M $2.43M $3.01M $3.01M
-Current Capital Lease Obligation $1.24M $1.85M $2.43M $3.01M $3.01M
Current Deferred Liabilities $6.36M $8.52M $10.07M $11.90M $11.90M
Other Current Liabilities $1.75M $1.62M $1.50M $1.06M $1.06M
Total Non-Current Liabilities $5.13M $6.49M $7.59M $8.10M $8.10M
Non-Current Deferred Liabilities $4.45M $5.65M $6.60M $6.96M $6.96M
Other Non-Current Liabilities $681,000.00 $837,000.00 $991,000.00 $1.14M $1.14M
Total Equity $352.59M $345.55M $394.88M $352.46M $352.46M
Stockholders' Equity $352.59M $345.55M $394.88M $352.46M $352.46M
Capital Stock $6,000.00 $6,000.00 $6,000.00 $5,000.00 $5,000.00
-Common Stock $6,000.00 $6,000.00 $6,000.00 $5,000.00 $5,000.00
Additional Paid-In Capital $1.04B $955.42M $942.70M $849.62M $849.62M
Retained Earnings -$682.98M -$609.34M -$547.72M -$497.72M -$497.72M
Gains/Losses Not Affecting Retained Earnings -$1.05M -$542,000.00 -$115,000.00 $543,000.00 $543,000.00
Restricted Cash – $494,000.00 $494,000.00 $494,000.00 $494,000.00
-Accumulated Depreciation – – – -$10.15M -$10.15M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$62.69M -$56.59M -$60.58M $45.59M -$30.45M
Net cash flow from continuing operations -$62.69M -$56.59M -$60.58M $45.59M -$30.45M
Net Income from Continuing Operations -$73.64M -$61.62M -$50.00M -$6.89M -$57.93M
Depreciation & Depletion & Amortization $455,000.00 $458,000.00 $439,000.00 $1.77M $405,000.00
Other Non-Cash Items $637,000.00 $680,000.00 $608,000.00 $2.41M $650,000.00
Change in Working Capital -$816,000.00 -$6.54M -$20.01M $16.35M $16.98M
-Change in Receivables -$1.36M -$2.73M $1.49M -$4.27M $3.31M
-Change in Prepaid Assets -$4.15M -$3.91M -$3.59M -$545,000.00 $220,000.00
-Change in Payables and Accrued Expense $8.06M $2.60M -$15.72M $21.29M $8.90M
-Change In Other Working Capital -$3.36M -$2.49M -$2.19M -$130,000.00 $4.54M
Net cash flow from investing -$10.21M $9.02M $50.69M -$186.81M -$61.06M
Net Cash Flow from Continuing Investing Activities -$10.21M $9.02M $50.69M -$186.81M -$61.06M
Net PPE Purchase and Sale -$2.85M -$1.98M -$353,000.00 -$670,000.00 -$232,000.00
Net Investment Purchase and Sale -$7.36M $10.99M $51.05M -$186.14M -$60.83M
Financing Cash Flow $70.16M $1.91M $84.33M $97.39M $92.34M
Net Cash Flow from Continuing Financing Activities $70.16M $1.91M $84.33M $97.39M $92.34M
Net Common Stock Issuance $65.70M $0.00 $80.66M $87.78M $87.78M
Proceeds from Stock Option Exercised $4.47M $1.91M $3.67M $9.61M $4.56M
Ending Cash Balance $110.99M $113.73M $159.38M $84.94M $84.94M
Net Change in Cash -$2.73M -$45.66M $74.44M -$43.84M $826,000.00
Beginning Cash Balance $113.73M $159.38M $84.94M $128.78M $84.12M
Free Cash Flow -$65.54M -$58.56M -$60.94M $44.92M -$30.69M
Gain/Loss from Continuing Operations – – – $145,000.00 $153,000.00

Discussion

No comments yet — be the first to weigh in on STOK.

Sign in to join the discussion.

Scroll to Top